NCT01107392 - Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia | Biotech Hunter

Enrollment

315

Participants

Timeline

Start Date

August 1, 2010

Primary Completion Date

March 16, 2012

Study Completion Date

June 8, 2012

Conditions

Benign Prostatic Hyperplasia

Interventions

DRUG

botulinum toxin Type A

botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.

DRUG

Normal saline

Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.

Trial Locations (8)

Newport Beach

Surrey

Prague

Paris

Munich

Manila

Poznan

Seoul